|
|
|
Volumn 14, Issue 5, 2000, Pages
|
|
FDA approves irinotecan as first-line therapy for colorectal cancer.
[No Author Info available]
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC AGENT;
CAMPTOTHECIN;
DNA TOPOISOMERASE;
DRUG DERIVATIVE;
ENZYME INHIBITOR;
IRINOTECAN;
ARTICLE;
COLORECTAL TUMOR;
DRUG ANTAGONISM;
FOOD AND DRUG ADMINISTRATION;
HUMAN;
PHASE 3 CLINICAL TRIAL;
QUALITY OF LIFE;
QUESTIONNAIRE;
UNITED STATES;
ANTINEOPLASTIC AGENTS, PHYTOGENIC;
ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS;
CAMPTOTHECIN;
CLINICAL TRIALS, PHASE III;
COLORECTAL NEOPLASMS;
DNA TOPOISOMERASES, TYPE I;
ENZYME INHIBITORS;
HUMANS;
QUALITY OF LIFE;
QUESTIONNAIRES;
UNITED STATES;
UNITED STATES FOOD AND DRUG ADMINISTRATION;
|
|
EID: 8544280884
PISSN: 08909091
EISSN: None
Source Type: Journal
DOI: None Document Type: Article |
|
Times cited : (11)
|
|
References (0)
|